Irish Haemophilia Society, Cathedral Court, Dublin, Ireland.
Haemophilia. 2011 Jan;17(1):35-40. doi: 10.1111/j.1365-2516.2010.02362.x. Epub 2010 Aug 16.
In 2009, a questionnaire was circulated to 19 national haemophilia patient organizations in Europe affiliated to the European Haemophilia Consortium (EHC) and the World Federation of Hemophilia (WFH) to seek information about the organization of haemophilia care and treatment available at a national level. The responses received highlighted differences in the level of care despite the recent promulgation of consensus guidelines designed to standardize the care of haemophilia throughout the continent of Europe. There was a wide range in factor VIII consumption with usage ranging from 0.38 IU per capita in Romania to 8.7 IU per capita in Sweden (median: 3.6 IU per capita). Despite the specific inclusion of coagulation factor concentrate in the WHO list of essential medications, cryoprecipitate is still used in some eastern European countries.
2009 年，向欧洲血友病患者组织联盟（EHC）和世界血友病联盟（WFH）下属的 19 个欧洲国家血友病患者组织分发了一份问卷，旨在了解国家层面血友病治疗和护理的组织情况。尽管最近颁布了旨在规范整个欧洲大陆血友病治疗的共识指南，但收到的回复强调了尽管存在差异，尽管最近颁布了旨在规范整个欧洲大陆血友病治疗的共识指南，但护理水平仍存在差异。VIII 因子的使用量差异很大，从罗马尼亚的人均 0.38IU 到瑞典的人均 8.7IU（中位数：人均 3.6IU）。尽管凝血因子浓缩物已被世界卫生组织列入基本药物清单，但在一些东欧国家仍在使用冷沉淀。
